Drug Development
Otsuka Discontinues Alzheimer’s Agitation Drug Development Following Second Unsuccessful Trial
Otsuka, Alzheimer’s disease, agitation, drug development, clinical trials, failed trials, discontinuation
Biogen Expands Immunology Portfolio with $1.15 Billion Acquisition of HI-Bio
Biogen, HI-Bio, acquisition, immunology, $1.15 billion, expansion, therapeutics, drug development
AstraZeneca’s Ambitious Vision: Pursuing $80 Billion in Revenue and 20 New Drugs by 2030
AstraZeneca, revenue target, new drugs, 2030, growth strategy, pharmaceutical industry, healthcare innovation, biotechnology, drug development, market expansion.
Revolutionizing Drug Discovery: Sanofi, OpenAI, and Formation Bio Join Forces
Sanofi, OpenAI, Formation Bio, AI, drug development, partnership, drug discovery, pharmaceuticals, artificial intelligence, healthcare innovation.
AltruBio Secures $225M for Midphase Ulcerative Colitis Program Following Checkpoint Drug Modification
AltruBio, checkpoint drug, ulcerative colitis, $225M funding, midphase program, biotechnology, drug development, healthcare innovation.
AstraZeneca Targets $80 Billion in Revenue by 2030: A Rapid Growth Trajectory
AstraZeneca, revenue target, 2030, growth trajectory, pharmaceutical industry, drug development, healthcare solutions.
Biogen and Ionis Discontinue ALS Drug Development Following Unsuccessful Early Trials
Biogen, Ionis, ALS, drug development, early-stage trial, disappointing results, discontinuation, neurological disorder, treatment research.
Blackstone Invests $300M in Uniquity Bio to Unleash Merck Drug’s Inflammation & Immunology Potential
Blackstone, Uniquity Bio, Merck, Inflammation & Immunology, Investment, Drug Development, Biotechnology
AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership
AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.
Ajax Pharmaceuticals Secures $95 Million for JAK Inhibitor Drug Development
Ajax Pharmaceuticals, JAK inhibitors, drug development, funding, investment, inflammatory diseases, autoimmune disorders, cancer.